This presentation examines evolving therapeutic antibody processes. Processing of conventional mAbs continues to mature, while new chromatography approaches are required for multispecifics and fragments as a one-size-fits-all strategy has become outdated. Optimising capture requires selecting processes based on the target molecule, development stage, scale-up plans, and budgets. Moreover, antibody variants are challenged with aggregation and product-related impurities. We will evaluate strategies focused on resin selection, operation mode, and process conditions to boost purity, yield, and productivity, including new protein A resins.
